Search
forLearn
5 / 801 resultslearn PTD-DBM
learn Aminexil
learn amino acids blend
learn Selenium AAC
Research
5 / 1000+ resultsresearch Research on Hair Bleach that Causes Less Hair Damage and Smells Less Pungent than Ammonium Hydroxide
AMPD is a better and less damaging alternative to ammonium hydroxide for hair bleaching.
research Pancytopenia in epidemic dropsy: a case report
Contaminated mustard oil caused severe health issues, including pancytopenia, in a family.
research Finasteride: A slow-binding 5.alpha.-reductase inhibitor
Finasteride slowly binds to 5-alpha-reductase, affecting enzyme stability and inhibitor potency.
research A genomic approach to susceptibility and pathogenesis leads to identifying potential novel therapeutic targets in androgenetic alopecia
Genomic approach finds new possible treatments for hair loss.
research Anogenital distance as a biomarker for incomplete masculinization : Molecular mechanisms in the perineum
A short male anogenital distance may indicate incomplete masculinization due to disrupted androgen action.
Community Join
5 / 1000+ resultscommunity DUPA VS. FAPD, which is more treatable? Which is worse?
DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Amplifica AMP-303 study results are expected late this summer
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
community Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.